Humacyte.

> Humacyte, which is developing bioengineered tissue for use in various indications, landed a financing agreement worth as much as $160 million with Oberland Capital Management, a New York-based private investment firm. The deal includes an upfront payment of $40...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT